Documentdetail
ID kaart

doi:10.1186/s40035-021-00250-5...

Auteur
Xu, Xiaojiao Shen, Dingding Gao, Yining Zhou, Qinming Ni, You Meng, Huanyu Shi, Hongqin Le, Weidong Chen, Shengdi Chen, Sheng
Langue
en
Editor

BioMed Central

Categorie

Neurology

Jaar

2021

vermelding datum

08-12-2022

Trefwoorden
amyotrophic lateral sclerosis motor neurons autophagy stem cells gene editing progression therapies als
Metriek

Beschrijving

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease involving both upper and lower motor neurons, leading to paralysis and eventually death.

Symptomatic treatments such as inhibition of salivation, alleviation of muscle cramps, and relief of spasticity and pain still play an important role in enhancing the quality of life.

To date, riluzole and edaravone are the only two drugs approved by the Food and Drug Administration for the treatment of ALS in a few countries.

While there is adequate consensus on the modest efficacy of riluzole, there are still open questions concerning the efficacy of edaravone in slowing the disease progression.

Therefore, identification of novel therapeutic strategies is urgently needed.

Impaired autophagic process plays a critical role in ALS pathogenesis.

In this review, we focus on therapies modulating autophagy in the context of ALS.

Furthermore, stem cell therapies, gene therapies, and newly-developed biomaterials have great potentials in alleviating neurodegeneration, which might halt the disease progression.

In this review, we will summarize the current and prospective therapies for ALS.

Xu, Xiaojiao,Shen, Dingding,Gao, Yining,Zhou, Qinming,Ni, You,Meng, Huanyu,Shi, Hongqin,Le, Weidong,Chen, Shengdi,Chen, Sheng, 2021, A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?, BioMed Central

Document

Openen

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Bone metastasis prediction in non-small-cell lung cancer: primary CT-based radiomics signature and clinical feature
non-small-cell lung cancer bone metastasis radiomics risk factor predict cohort model cect cancer prediction 0 metastasis radiomics clinical